Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).

Autor: Softic L; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Brillet R; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Berry F; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Ahnou N; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Nevers Q; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Morin-Dewaele M; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Hamadat S; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Bruscella P; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France., Fourati S; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France.; Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France., Pawlotsky JM; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France jean-michel.pawlotsky@aphp.fr.; Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France., Ahmed-Belkacem A; Research Team 'Viruses, Hepatology, Cancer,' Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France.
Jazyk: angličtina
Zdroj: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Jun 23; Vol. 64 (7). Date of Electronic Publication: 2020 Jun 23 (Print Publication: 2020).
DOI: 10.1128/AAC.00876-20
Abstrakt: Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC 50 ) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
(Copyright © 2020 American Society for Microbiology.)
Databáze: MEDLINE
Externí odkaz: